KOLINPHARMA® obtains a patent in the United States of America for Dolatrox® - 10/03/2020

Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem...

The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t...

A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...

The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

Our From the Floor live blog returns to Philadelphia for CPHI Americas 2026, continuing to showcase the entire pharmaceutical supply chain from north to south across the Americas.

In this exclusive interview, Jim Donovan, VP and General Manager of Pfizer CentreOne, shares real-world insights on navigating the toughest challenges in ADC and biologics manufacturing: from high-containment conjugation and accelerated tech trans...

The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...

Anil Kane, PhD, MBA, serves as the Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, a global leader in scientific research and innovation. In this exclusive interview, Kane shares his and Thermo Fisher&#...